GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] can we stop arguing about TRIUMPH until somebody posts a number — 62 comments in the full submission. View in context.
1.2k
c/trialwatch·submitted 1 year ago by u/line_demir

[Discussion] can we stop arguing about TRIUMPH until somebody posts a number

Discussionbranch of 8 comments

Trying to get a straight answer on this: can we stop arguing about TRIUMPH until somebody posts a number. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. Read a press release and the publication three months apart. The hedging in the second…

Read the full submission and all 62 comments →

This branch

8 comments, started 1 year ago
u/britta_boateng55 points·1 year ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/foam_head_fred19 points·1 year ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/customs_seizure_sid37 points·1 year ago

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

replysharereportpermalink
u/line_demirOP28 points·1 year ago

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

replysharereportpermalink
u/camila_vasquez7 points·1 year ago

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

replysharereportpermalink
u/line_demirOP21 points·1 year ago

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

replysharereportpermalink
u/nightowl_injector10 points·1 year ago

the appendix is where the interesting tables live

replysharereportpermalink
u/line_demirOP30 points·1 year ago·edited

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.